medwireNews: The US FDA has approved adalimumab-adbm as the first interchangeable biosimilar drug to treat inflammatory arthritis and certain other immune-mediated diseases.
Originally approved as a biosimilar product in 2017, adalimumab-adbm may now be used as an interchangeable biosimilar, meaning it may be substituted for the originator without the need for a change in prescription.
Adalimumab-adbm is approved in the USA for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis, as well as other diseases including plaque psoriasis and inflammatory bowel disease.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group